francesco giorgino diabete

Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Email: KEYWORDS:COVID-19, diabetes, lung, SARS-CoV-2 The SARS-CoV-2 infection is spreading fast and represents a menac-ing threat to global health. Published on 01 Feb 2020. Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers. Diabetes Care. The possible role of post‐prandial hyperglycaemia in the pathogenesis of diabetic complications. Trulicity [Prescribing Information]. 2017 Dec 28;64(12):1165-1172. doi: 10.1507/endocrj.EJ17-0189. Francesco Giorgino Send a message. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. 2001;24(4):631‐636. 2003;163:1306‐1316. Pozzilli P, Norwood P, Jódar E, Davies MJ, Ivanyi T, Jiang H, Woodward DB, Milicevic Z. Diabetes Obes Metab. View ePoster. Silvio Inzucchi and Sarah Jarvis. 2017;40(3):291‐300. National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error, Change from baseline in glycaemic measures and body weight at 52 weeks by subgroups in people treated with dulaglutide 1.5 mg or insulin glargine. AstraZeneca, Cambridge, UK. 2003;46(Suppl 1):M9‐M16. Diabetes Care. Changes in glycaemic measures in response to treatment with dulaglutide or glargine were evaluated in each subgroup. He also said the individual circumstances are important when considering which treatment option to go with, including whether the patient is obese or whether they are already featuring a decrease in renal function. Francesco Giorgino sui naufragi nel Mediterraneo: ‘Il … Key efficacy and safety outcomes. We categorized participants into four subgroups based on prespecified glucose thresholds and their baseline FG and daily 2-hour mean PPG: low FG/low PPG; low FG/high PPG; high FG/low PPG; and high FG/high PPG. Diabetes mellitus is a chronic common metabolic disorder . Diabetes in the Time of COVID-19: A Twitter-Based Sentiment Analysis Show all authors. HHS Le importanti dichiarazione del prof. Francesco Giorgino, prestigioso accademico specialista medico, che da anni si occupa di obesità, diabete mellito e … The long-acting glucagon-like peptide-1 receptor agonist dulaglutide acts by stimulating insulin secretion and reducing glucagon levels in a glucose-dependent manner both in the fasting and postprandial states, resulting in reductions of both fasting glucose (FG) and postprandial glucose (PPG). Epub 2017 Apr 10. © 2020 MJH Life Sciences and HCPLive. 0 views XX downloads; XX citations; Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed‐ratio combination: a post hoc analysis of the LixiLan‐O and LixiLan‐L trials. The aim of the present post hoc analysis of the phase 3 AWARD-2 trial was to investigate whether specific baseline glycaemic patterns respond differentially to dulaglutide compared to insulin glargine (glargine). Prof. Francesco Giorgino Bari, 2 febbraio 2008 Vecchi e Nuovi Farmaci nel Trattamento del Diabete Tipo 2 Dipartimento dell’Emergenza e dei Trapianti di Organi Sezione di Medicina Interna, Endocrinologia e Malattie Metaboliche Università degli Studi di Bari 1°Congresso Regionale SIMG Puglia Il Farmaco come Risorsa per la Salute. The … 2017 Jul;19(7):1024-1031. doi: 10.1111/dom.12937. 1.UNA PANDEMIA CHE AVANZA. At 52 weeks, significant reductions from baseline in glycated haemoglobin (HbA1c) were observed in all subgroups with dulaglutide 1.5 mg and with glargine (all P < .05), except in patients with low FG/low PPG who received glargine. 1. A major breakthrough in diabetes treatment in the last few years has been the advent of SGLT2 inhibitors as a medication that also assists in helping with kidney function, while lowering the risk of cardiovascular events. Francesco Giorgino, MD, 1 Alka Shaunik, MD, 2 Minzhi Liu, PhD, 2 and Aramesh Saremi, MD 2 Author ... Diabetes is associated with accelerated risk of atherosclerosis. Diapositiva preparata da FRANCESCO GIORGINO e ceduta alla Società Italiana di Diabetologia. his artworks are characterized by child like figures, simple monochromatic lines combined with a dash of color, and elements of architecture. Jiten Vora MD. Welcome and introduction. Search for more papers by this author. This site needs JavaScript to work properly. Epub 2016 Aug 12. All rights reserved. Generation of cyclic AMP (cAMP) and activation of protein kinase A (PKA) and Epac proteins appear to be involved in stim- ulation of insulin secretion by GLP-1. Metformin should remain as ‘foundation therapy’ for the majority of patients with T2D: Yes (Francesco Giorgino) or No (Nikolaus Marx) Silvio Inzucchi and Francesco Giorgino. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. The long-acting glucagon-like peptide-1 receptor agonist dulaglutide acts by stimulating insulin secretion and reducing glucagon levels in a glucose-dependent manner both in the fasting and postprandial states, resulting in reductions of both fasting glucose (FG) and postprandial glucose (PPG). Postgrad Med. Francesco Giorgino . Kaneko S, Oura T, Matsui A, Shingaki T, Takeuchi M. Endocr J. Epub 2015 Jun 18. Francesco Giorgino, Marian Benroubi, Jui-Hung Sun, Alan G. Zimmermann, Valeria Pechtner Diabetes Care Dec 2015, 38 (12) 2241-2249; DOI: 10.2337/dc14-1625 Share This Article: Copy Clinical significance, pathogenesis, and management of postprandial hyperglycaemia. GLP-1; basal insulin; dulaglutide; type 2 diabetes.  |  |  All rights reserved. In 2014, the global prevalence of diabetes was estimated to be 9% among adults aged more than 18 years . Download. Consenso informato. Diabetes Ther. 2015 Dec;38(12):2241-9. doi: 10.2337/dc14-1625. NIH Diabetes Obes Metab. 2020 Feb;80(2):197-208. doi: 10.1007/s40265-020-01260-9., Gerich J. Please enable it to take advantage of the complete set of features! Contribution to sentiment. The GLP-1RA could also inhibit the further reduce the development of arthrosclerosis and the incidence of stroke and cardiovascular events in type 2 diabetes. The relationship between glucose control and cardiovascular outcomes in type 2 diabetes has been a matter of controversy over the years. -, Riddle MC. Basal glucose can be controlled, but the prandial problem persists‐It's the next target! Basal insulin therapy in type 2 diabetes: 28‐week comparison of insulin glargine (HOE 901) and NPH insulin. Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice? By Kamlesh Khunti, Francesco Giorgino, Lori Berard, Dídac Mauricio — Abstract Achieving target glycaemic control is essential in people with diabetes to minimize the risk of long‐term complications, and many people with type 2 diabetes will ultimately require basal insulin (BI) therapy to achieve their individualized glycaemic targets. Francesco Giorgino and Nikolaus Marx. Epub 2017 Feb 17. Overall, Giorgino suggests both treatments could be combined for the benefit of many patients. Change from baseline in glycaemic measures and body weight at 52 weeks by…, NLM Dr. Giorgino discusses how combining SGLT2 Inhibitors and GLP-1RA could be combined for treating type 2 diabetes. Figure 1. Epub 2017 Oct 5. Visualizza il profilo di Francesco Giorgino su LinkedIn, la più grande comunità professionale al mondo. Francesco Giorgino Scritto da il 27 Settembre 2020 To assess perceptions related to erectile dysfunction (ED) and premature eja...The latest recommendations from the American Diabetes Association and the European Association for the Study of Diabetes prioritize the use of drugs with proven cardiovascular (CV) benefit in patients with established CV disease. Angelo Cignarelli, MD, PhD 1. Simultaneous vs sequential combination of insulin glargine and lixisenatide in type 2 diabetes uncontrolled on metformin ePoster # 795 View ePoster. Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. gennaio 11, 2016 Supplemental Figure 2: Correlation analysis between uAQP5 and uACR or CKD-EPI. Guarda il profilo completo su LinkedIn e scopri i collegamenti di Francesco e le offerte di lavoro presso aziende simili. Open in new tab . Francesco Giorgino, Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Piazza Giulio Cesare, 11, 70124 Bari, Italy. Lo studio presentato in questo articolo non ha richiesto sperimentazione umana. Angelo Cignarelli . Giorgino / Diabetes Research and Clinical Practice 74 (2006) S152–S155 S153 Fig.  |  Search for more papers by this … Francesco Giorgino, Università di Bari, IBDO Foundation Gerardo Medea, SIMG, IBDO Foundation Paolo Sbraccia, Università di Roma "Tor Vergata", IBDO Foundation Federico Spandonaro, Università Roma "Tor Vergata", IBDO Foundation Ketty Vaccaro, Fondazione CENSIS, IBDO Foundation. During the 18th World Congress of Insulin Resistance Diabetes & Cardiovascular (WCIRDC) Online CME Conference presented by the Metabolic Institute of America (TMIOA), Francesco Giorgino, MD, PhD, professor of Endocrinology and Metabolism, chief of the Division of Endocrinology, and Director of the Specialty School of Endocrinology and Metabolism at the University Hospital Policlinico Consorziale, University of Bari Aldo Moro, presented new information about using SGLT2 inhibitors, GLP-1RA, or an initial combination of both as treatment for type 2 diabetes. 2016 Nov;128(8):810-821. doi: 10.1080/00325481.2016.1218260. Francesco Giorgino As seen in: Color Research & Application ... .com — Abstract Approximately 50% of patients with type 2 diabetes mellitus (T2DM) do not achieve glycemic targets and require treatment intensification. Drugs. are employees and shareholders of Eli Lilly and Company. -, Ceriello A. Lisbon 2017. Data presented as least squares mean (95% CI); intention‐to‐treat population, without post‐rescue visits. M.Y., Z.M., A.H. and L.E.G.P. Per ricevere la versione originale si prega di scrivere a GLUT1/2, glucose transporter 1/2; SGLT1/2, sodium –glucose co -transporter 1/2 1. Authors Francesco Giorgino 1 , Marian Benroubi 2 , Jui-Hung Sun 3 , Alan G Zimmermann 4 , Valeria Pechtner 5 Affiliations 1 University of Bari Aldo Moro, Bari, Italy. See this image and copyright information in PMC. Get the latest public health information from CDC:, Get the latest research information from NIH:, Find NCBI SARS-CoV-2 literature, sequence, and clinical content: Email: Epub 2020 Jun 20. Download in PowerPoint. Keywords: Dulaglutide: A Review in Type 2 Diabetes. Gallwitz B, Dagogo-Jack S, Thieu V, Garcia-Perez LE, Pavo I, Yu M, Robertson KE, Zhang N, Giorgino F. Diabetes Obes Metab. -. Epub 2017 Sep 14. © 2020 MJH Life Sciences™ and HCPLive. Francesco Giorgino; Non categorizzato. Diabetologia. Per ricevere la versione originale si prega di scrivere a Il Prof Francesco Giorgino dichiara di aver ricevuto negli ultimi due anni compensi o finanziamenti dalle … L'intervista del professor Francesco Giorgino, del dipartimento di Endocrinologia dell’Università di Bari, ai microfoni di Controradio. © 2019 The Authors. Giorgino explained in an interview with HCPLive®, how these medications have shaped treatment plans for patients with type 2 diabetes. Anderson JE, Thieu VT, Boye KS, Hietpas RT, Garcia-Perez LE. Clipboard, Search History, and several other advanced features are temporarily unavailable. Francesco ha indicato 6 esperienze lavorative sul suo profilo. Department of Diabetes and Endocrinology, University of Liverpool, Liverpool, UK . Cross-specialty debates in diabetes. Thus far, SGLT2 inhibitors have shown efficacy in reducing hospitalizations for heart failure and effect positively the decline in renal function in type 2 diabetes. Schematic representation of the major signaling pathways through which GLP-1 activates multiple biological responses in β- cells. View Abstract . Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2) Diabetes Care. Greater HbA1c reductions were observed with dulaglutide 1.5 mg compared to glargine in all subgroups (all P ≤ .05), except in the low FG/high PPG subgroup. Francesco Giorgino Show Co-Speakers Efficacy and safety of once weekly dulaglutide vs insulin glargine in combination with metformin and glimepiride in type 2 diabetes patients (AWARD-2) Professor Giorgino’s research interests include the mechanisms leading to insulin resistance and beta-cell dysfunction in Type 2 diabetes with a particular focus on skeletal muscle metabolism and organ cross-talk, inflammation and lipotoxicity, and the effects of diabetes drugs on pancreatic islets and the cardiovascular system. Studi sugli animali View Abstract. Francesco Giorgino; International Journal of Obesity. Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes. L’autore Francesco Giorgino dichiara di aver ricevuto compensi per collaborazione scientifica da Abbott, Roche Diabetes Care, Lifescan. 2018 Feb;20(2):409-418. doi: 10.1111/dom.13086. Diapositiva preparata da FRANCESCO GIORGINO e ceduta alla Società Italiana di Diabetologia. 2018. 451 views . Partial data from this study have been previously presented at the American Diabetes Association 78th Annual Scientific Sessions, held in Orlando, Florida, June 22–26, 2018, and at the 54th Annual Meeting of the European Association for the Study of Diabetes, held in Berlin, Germany, October 1–5, 2018. 29 Settembre 2020. Francesco Giorgino, University of Bari Aldo Moro, Piazza Giulio Cesare, n. 11, Bari, 70124, Italy. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. Department of Emergency and Organ Transplantation Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy View ORCID profile See all articles by this author. COVID-19 is an emerging, rapidly evolving situation. In 2016, more than 3.2 million people in Italy were reported to suffer from diabetes, representing 5.3% of the total population (16.5% among people aged 65 and over) . Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. F.G. serves or has served on the advisory boards for AstraZeneca, Eli Lilly and Company, Roche Diabetes Care, and NovoNordisk, serves or has served as a consultant for AstraZeneca, Boehringer‐Ingelheim, Lifescan, Merck Sharp & Dohme and Sanofi, and has received research support from AstraZeneca, Eli Lilly and Company, Lifescan and Takeda. Eli Lilly and Company. Search for more papers by this author. In contrast, the main mechanism of action of basal insulin is to reduce elevated FG by inhibiting hepatic glucose production. 2020 Aug;11(8):1627-1638. doi: 10.1007/s13300-020-00863-5. *. francesco giorgino, ravi retnakaran, josep vidal, vanita aroda, aramesh saremi, minzhi liu Diabetes Jul 2018, 67 (Supplement 1) 1095-P; DOI: 10.2337/db18-1095-P Share This Article: Copy Consistently, in 2018, the diabetes tweets mostly expressed emotions of trust, fear, and anticipation, whereas in 2020, fear was the most represented emotion, followed by sadness . -, Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. L’autore Giuseppe Lisco dichiara di non avere conflitti di interesse. Arch Intern Med. Peter Fenici MD.

Itinerari Bologna Trekking, Solo Baglioni Testo, L'età Comunale In Italia Letteratura, Love Story Piano Pdf, Poeti Maledetti Frasi, Ristoranti Centro Padova, Codice Ufficio A51, Mito Orsa Maggiore Scuola Primaria, Riassunto Diritto Del Lavoro 2019, Gmat Practice Exam 1 And 2, Mia Martini Famiglia, Citazioni Sul Tempo,